Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 26, 2009

ThromboGenics and BioInvent Receive $6.5M Fee from Roche under Deal Covering Anticancer mAb

  • ThromboGenics and BioInvent received a technology transfer success fee of €5 million, or $6.5 million, from Roche. Payment is as per an alliance between the firms covering anticancer antibody, TB-403.

    The TB-403 strategic alliance with Roche was signed in June 2008. ThromboGenics and BioInvent received E50 million at the time and could earn up to E450 million following completion of a series of development and commercial milestones.

    Additionally Roche will pay double-digit royalties on future sales. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of the revenue from the deal.

    TB-403 is an anti-PIGF humanized mAb that blocks the formation of the new blood vessels required by solid tumors to support growth. PlGF is a homologue of VEGF, and clinical evidence suggests that it plays a role in the angiogenesis of malignant tissue and does not affect normal tissue angiogenesis.

    ---

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »